Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed Starts China POC Trial of Novel mAb in Autoimmune Disease

publication date: Apr 22, 2020

Harbour BioMed has dosed the first patient in a China Phase Ib/IIa trial of its anti-FcRn antibody to treat an autoimmune disease, neuromyelitis optica spectrum disorder (NMOSD). The trial is the first proof-of-concept study of an anti-FcRn antibody in patients with NMOSD. Batoclimab targets the neonatal Fc receptor (FcRn) to accelerate the degradation of autoantibodies that drive NMOSD and other autoimmune disorders. HBM, a company with operations in Boston, Rotterdam and Suzhou, in-licensed greater China rights to batoclimab from Korea's HanAll Biopharma in an $81 million agreement. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital